UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 5, 2025

 

BioNexus Gene Lab Corp.

(Exact name of Company as specified in its charter)

 

Wyoming

 

001-41750

 

35-2604830

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification Number)

 

Unit A-28-7, Tower A, Menara UOA Bangsar,

No.5 Jln Bangsar Utama 1,

59000 Kuala Lumpur

(Address of principal executive offices)

 

Phone: +1 (307) 241-6898

(Company’s Telephone Number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, no par value

 

BGLC

 

Nasdaq

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01 Other Events

 

On March 5, 2025, BioNexus Gene Lab Corp. (the “Company”) issued a press release announcing that its Board of Directors has formally approved a new treasury strategy focused exclusively on Ethereum (ETH) as a strategic treasury asset. This decision positions the Company as a leader among Nasdaq-listed companies in prioritizing Ethereum for treasury management. The press release further states that this strategy aligns with recent announcements regarding Ethereum’s inclusion in the proposed U.S. Crypto Strategic Reserve.

 

In connection with this announcement, the Company has released an Ethereum Strategy Whitepaper, which provides detailed insight into the rationale for adopting Ethereum as a treasury asset. The whitepaper is publicly available on the Company’s website at www.bionexusgenelab.com/ethstrategy.

 

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 8.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statement and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

 

Description

99.1

 

Press release announcing the Company’s new Ethereum focused treasury strategy.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BioNexus Gene Lab Corp.

 

 

/s/ Su-Leng Tan Lee

 

By:

Su-Leng Tan Lee

 

 

Chief Executive Officer

 

 

 

 

Date:

March 5, 2025

 

 

 
3

 

nullv3.25.0.1
Cover
Mar. 05, 2025
Cover [Abstract]  
Entity Registrant Name BioNexus Gene Lab Corp.
Entity Central Index Key 0001737523
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company true
Document Period End Date Mar. 05, 2025
Entity Ex Transition Period false
Entity File Number 001-41750
Entity Incorporation State Country Code WY
Entity Tax Identification Number 35-2604830
Entity Address Address Line 1 Unit A-28-7, Tower A
Entity Address Address Line 2 Menara UOA Bangsar
Entity Address Address Line 3 No.5 Jln Bangsar Utama 1
Entity Address City Or Town Kuala Lumpur
Entity Address Postal Zip Code 59000
City Area Code 307
Local Phone Number 241-6898
Security 12b Title Common Stock, no par value
Trading Symbol BGLC
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
BioNexus Gene Lab (NASDAQ:BGLC)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025 Plus de graphiques de la Bourse BioNexus Gene Lab
BioNexus Gene Lab (NASDAQ:BGLC)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025 Plus de graphiques de la Bourse BioNexus Gene Lab